Neoplasms

Digestive System Diseases

All Conditions

Carcinoma, Hepatocellular

Liver Neoplasms

Carcinoma

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy

Cinobufacin injection

changquan Ling, Doctor

Ling chang quan, doctor

Cinobufacini has the effects of anticancer, improving the liver function, elevation of immunity and little side effects, and is important and significant for the patients with hepatitis, liver cirrhosis and hepatomas.

Compared with transarterial chemoembolization (TACE) , the clinical effect of cinobufacini is non-inferior/ equivalent.Compared with TACE, cinobufacini is superior in security .

Inclusion criterion :

1. The sex does not limit, age:18-70 years old .
2. The patients have inoperable advanced hepatoma without serious disorder in liver and renal, tumor occupation\< 70 %
3. The patients have failure in surgical intervention or resection operation recidivist
4. Hepatic function Child-pugh A、B
5. All the cases have the definite final diagnosis of imageology results such as MRI、CT 、B ultrasonic or cytology results
6. The patient's prediction of live time\>6 months, who can tolerant of TACE and has quality of life ECOG score\<3
7. The patients participate the clinical trial voluntarily and have already signed informed consent

Exclusion criterion :

1. Main portal vein was obstructed completely.
2. The occupation of tumor are 70 % or more than 70 % in the whole liver
3. The patient has TACE or other antineoplaston
4. After carcinosectomy the patient has the prophylactic
5. The patient is with renal inadequacy: Cr≥133 umol/L
6. Severe cardiovascular disease
7. The patient is with other diseases to influence the proposal

Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy

The Clinical Research of the Intermediate and Advanced Hepatoma Treated by Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy

The evaluation of the patient's respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD.

Changhai Hospital

Changquan Ling

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy	NCT01236690	Hepatoma Cinobufacin Inj...	Cinobufacin inj...	18 Years - 70 Years	Changhai Hospital
Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy	NCT01236690	Hepatoma Cinobufacin Inj...	Cinobufacin inj...	18 Years - 70 Years	Changhai Hospital

Spots Global Cancer Trial Database for cinobufacin injection